Industry report finds improving standards in Indian manufacturing

A McKinsey report commissioned by trade group the Indian Pharmaceutical Alliance (IPA) indicates that pharmaceuticals manufacturers in India are receiving a lower proportion of warning letters from the US Food and Drug Administration.

In 2015, half of all such letters were sent to Indian manufacturers, whereas last year the figure dropped to below a third.

Local press attribute the decline to investment in the training of staff, more automation and a closer working relationship with regulators. The IPA has also launched its own initiative to raise standards.